Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pyo-bacteriophage
- Development stage
- Phase 3
- Lead developer
- Eliava Biopreparations
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Intravesical
01
Overview
PYO Phage (also known as Pyo-bacteriophage) is a therapeutic cocktail of bacteriophages designed to treat purulent (pyogenic) bacterial infections. Originally developed by the Eliava Institute of Bacteriophages, Microbiology and Virology in Georgia, the cocktail typically contains lytic phages targeting five major groups of bacterial pathogens: Staphylococcus spp., Streptococcus spp., Escherichia coli, Pseudomonas aeruginosa, and Proteus spp. The mechanism of action involves the specific attachment of phages to bacterial cell walls, injection of viral DNA, intracellular replication, and subsequent lysis of the host bacteria, releasing new progeny phages to continue the cycle. In clinical research, notably a trial led by Balgrist University Hospital (NCT02139475), PYO Phage was evaluated via intravesical administration for the treatment of urinary tract infections in patients undergoing transurethral resection of the prostate (TURP).
- Brand names
- Pyo-bacteriophage
- Other names
- PYO PhagePyophagePyo-bacteriophage cocktail
02
Targets
P. aeruginosa (Pseudomonas aeruginosa)AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)
Beyond the preview
Go deeper on pyo-bacteriophage.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pyo-bacteriophage.